SandlerResearch.org adds Global Dermatophytic Onychomycosis Market 2016-2020 a new research reports in its store. The analysts forecast global Dermatophytic Onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.
Commenting on the report, an analyst said: "It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone. At times, the combination of surgery and systemic and topical therapies are also used. Sometimes, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy. Such trends will have a positive impact on the growth of the market."
According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.
For more information Inquire @ http://www.sandlerresearch.org/inquire-before-buying?rname=51777
Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.
Top vendors are Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis and Valeant Pharmaceuticals
Other Prominent Vendors in the market are: Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals and Viamet Pharmaceuticals.
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the
Key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
What are the strengths and weaknesses of the key vendors?
What are the strengths and weaknesses of the key vendors? Purchase report directly @ http://www.sandlerresearch.org/purchase?rname=51777 Single user copy USD2500
Table of Content for Global Dermatophytic Onychomycosis Market 2016-2020:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Overview: Dermatophytic onychomycosis
Types of dermatophytic onychomycosis
PART 06: Pipeline analysis
Luliconazole solution, 10%
PART 07: Market landscape
Market size and forecast
Five forces analysis
PART 08: Market segmentation by route of administration
PART 09: Geographical segmentation
Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
Dermatophytic onychomycosis market in Americas
Dermatophytic onychomycosis market in EMEA
Dermatophytic onychomycosis market in APAC
PART 10: Market drivers
Increase in R&D
Growing prevalence of dermatophytic onychomycosis
Unmet medical needs
Rise in prevalence of diabetes
PART 11: Impact of drivers
PART 12: Market challenges
Adverse effects and limited efficacy of drugs
Lack of awareness
Increased availability of generics and alternative therapies
Product recalls by US FDA
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies
Outsourcing of drugs manufacturing
Increase in strategic alliances among vendors
Incorporation of novel technology for product development
PART 15: Vendor landscape
Other prominent vendors
PART 16: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
Exhibit 02: Percentage of population undergoing treatment globally 2015
Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Comparison of activity of topical medications for onychomycosis
Exhibit 09: Comparison of activity of oral medications for onychomycosis
Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: Anacor Pharmaceuticals: Key takeaways
Exhibit 22: Galderma: Key takeaways
Exhibit 23: Janssen Biotech: Key takeaways
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Valeant Pharmaceuticals: Key takeaways
Complete report available at http://www.sandlerresearch.org/global-dermatophytic-onychomycosis-market-2016-2020.html
Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.